CAVU Biotherapies, Inc
USDA Authorized & State Veterinary Board Approved to Provide the
Autologous Prescription Product By CAVU (APP)
APP BY CAVU FOR CANCER
"It's Cancer."
According to a national survey from the Morris Animal Foundation, the number one concern of the American pet owner today is cancer. Based on North Carolina State University estimates and the number of dog owners in the U.S., an average of 19 families lose their dog family member per minute to cancer.
Current Therapies
But as many of us know personally, the current options can have physically devastating consequences and often don't yield the desired results. Less than 20% of dogs diagnosed with Stage IV B-cell Lymphoma will live 2 years post diagnosis with chemotherapy, surgery, and rescue therapies.
CAVU's Solution
Our vision is a world in which the immense power of the cellular immunes system can be harnessed to control cancer to improve quality of life.
Our belief is that our furry family members should have access to personalized immuno-services. CAVU wants to offer our veterinarians the latest, pro-active, immune-guided services to help improve treatment decision making.
It's Personal
Our Founder and CEO, Dr. Colleen O'Connor, lost two dogs to cancer. She watched helplessly as her wonderful Bichon Frise and loyal Toy Poodle lost their quality of life due to progressing tumors and lack of successful treatments. These losses motivated her. She has combined her knowledge and experience of oncology, immunology, and cellular therapies with her unbridled passion to provide our pets with a chance at a longer, more meaningful life.
USDA Approved Required Statement to Owners and Veterinarians:
Possible Benefits of Experimental Autologous Prescription Product by CAVU
The benefit to your dog associated with this service is not completely known. This is an experimental and individualized therapeutic. Efficacy and safety have not been established. Due to its personalized nature, individual results will vary, and no individual result should be seen as typical. Results are not guaranteed.
Experimental Autologous Prescription Product by CAVU Possible Toxicities:
Fever, decreased energy, malaise, gastrointestinal upset (vomiting, diarrhea, loss of appetite), metallic smell to the breath, vasculitis, tachycardia, shock, off-target tissue destruction, cytokine release syndrome, tumor lysis syndrome, lymph node swelling, pulmonary edema, seizures, transfusion-like related side effects, anaphylaxis, aggravation of immune- mediated disease, "Grade 4 Immune Reaction", and death.